Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.
Epigenetic modulation of neuroblastoma enhances T cell and NK cell immunogenicity by inducing a tumor-cell lineage switch.
复制标题
DOI:
10.1136/jitc-2022-005002
复制
发表时间:
2022-12
影响因子:
10.9
通讯作者:
中科院分区:
文献类型:
--
作者:
Immunotherapy in high-risk neuroblastoma (HR-NBL) does not live up to its full potential due to inadequate (adaptive) immune engagement caused by the extensive immunomodulatory capacity of HR-NBL. We aimed to tackle one of the most notable immunomodulatory processes in neuroblastoma (NBL), absence of major histocompatibility complex class I (MHC-I) surface expression, a process greatly limiting cytotoxic T cell engagement. We and others have previously shown that MHC-I expression can be induced by cytokine-driven immune modulation. Here, we aimed to identify tolerable pharmacological repurposing strategies to upregulate MHC-I expression and therewith enhance T cell immunogenicity in NBL. Drug repurposing libraries were screened to identify compounds enhancing MHC-I surface expression in NBL cells using high-throughput flow cytometry analyses optimized for adherent cells. The effect of positive hits was confirmed in a panel of NBL cell lines and patient-derived organoids. Compound-treated NBL cell lines and organoids were cocultured with preferentially expressed antigen of melanoma (PRAME)-reactive tumor-specific T cells and healthy-donor natural killer (NK) cells to determine the in vitro effect on T cell and NK cell cytotoxicity. Additional immunomodulatory effects of histone deacetylase inhibitors (HDACi) were identified by transcriptome and translatome analysis of treated organoids. Drug library screening revealed MHC-I upregulation by inhibitor of apoptosis inhibitor (IAPi)- and HDACi drug classes. The effect of IAPi was limited due to repression of nuclear factor kappa B (NFκB) pathway activity in NBL, while the MHC-I-modulating effect of HDACi was widely translatable to a panel of NBL cell lines and patient-derived organoids. Pretreatment of NBL cells with the HDACi entinostat enhanced the cytotoxic capacity of tumor-specific T cells against NBL in vitro, which coincided with increased expression of additional players regulating T cell cytotoxicity (eg, TAP1/2 and immunoproteasome subunits). Moreover, MICA and MICB, important in NK cell cytotoxicity, were also increased by entinostat exposure. Intriguingly, this increase in immunogenicity was accompanied by a shift toward a more mesenchymal NBL cell lineage. This study indicates the potential of combining (immuno)therapy with HDACi to enhance both T cell-driven and NKcell-driven immune responses in patients with HR-NBL.
登录
查看更多内容
影响因子:
5.8
作者:
Gu, Zuguang;Eils, Roland;Schlesner, Matthias
通讯作者:
Schlesner, Matthias
影响因子:
5.8
作者:
Briere, David;Sudhakar, Niranjan;Christensen, James G.
通讯作者:
Christensen, James G.
影响因子:
5.4
作者:
Dull, T;Zufferey, R;Naldini, L
通讯作者:
Naldini, L
影响因子:
16.6
作者:
Beug ST;Beauregard CE;Healy C;Sanda T;St-Jean M;Chabot J;Walker DE;Mohan A;Earl N;Lun X;Senger DL;Robbins SM;Staeheli P;Forsyth PA;Alain T;LaCasse EC;Korneluk RG
通讯作者:
Korneluk RG
DOI:
10.1016/j.omtm.2021.03.015
发表时间:
2021-06-11
期刊:
Molecular therapy. Methods & clinical development
影响因子:
--
作者:
Lo Presti V;Cornel AM;Plantinga M;Dünnebach E;Kuball J;Boelens JJ;Nierkens S;van Til NP
通讯作者:
van Til NP